uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
CARLISLE COMPANIES, Inc. (NYSE: CSL) Delayed: 317.85 +3.15 (1.00%)
Previous Close $314.70    52 Week High $114.49 
Open $321.80    52 Week Low $75.17 
Day High $321.80    P/E 88.05 
Day Low $310.39    EPS $3.61 
Volume 524,017       

(AMEX: CSLLY) Delayed: 31.91 +0.81 (2.60%)
Previous Close $31.10    52 Week High $45.60 
Open $31.80    52 Week Low $33.39 
Day High $31.96    P/E N/A 
Day Low $31.50    EPS $0.00 
Volume 46,032       

UNIQURE (NASDAQ: QURE) Delayed: 44.31 +0.31 (0.70%)
Previous Close $44.00    52 Week High $22.79 
Open $44.50    52 Week Low $6.63 
Day High $45.03    P/E N/A 
Day Low $43.81    EPS $0.00 
Volume 801,200